Charles River Lab, a drug development services company collaborating with the A-T Children’s Project, has succeeded in developing a laboratory test or “assay” to rapidly evaluate thousands of approved drugs to learn if some of them can be repurposed for A-T. Because drugs emerging from the screening process with promising results will have already been … Read More
As we head into 2022, research to find treatments for ataxia-telangiectasia (A-T) is moving more swiftly than ever. Please help us maintain momentum by making a year-end donation. Researchers at Boston Children’s Hospital are now treating a little girl with A-T using antisense oligonucleotide (ASO) gene therapy and will soon be expanding their testing to more children. … Read More
Dear Friends, I hope you and your families are remaining safe as Covid continues to throw new challenges at us. While the pandemic has made funding and operating the A-T Children’s Project vastly more difficult, we’re continuing to drive forward innovative research, knowing that our kids will keep deteriorating a little bit each day until … Read More
Hi everyone, I hope you and your families are continuing to stay safe during the pandemic. Over the past year, you’ve heard me talk a lot about testing an approach called antisense oligonucleotide (ASO) gene therapy in a little girl with A-T. She has continued to receive regular injections, and we’re grateful that we haven’t … Read More
Hi everyone, I hope you and your family are doing well and keeping safe. As much as the COVID-19 pandemic has changed our world, I wanted to let you know that our ASO gene therapy trial for A-T – that you helped make possible – has not stopped. It continues forward, bringing hope to many … Read More
It’s been several months since I last updated you on our progress toward testing an antisense oligonucleotide (ASO) gene therapy in a child with A-T. In this update, I thought I’d go a little deeper on a couple aspects of our development efforts, including some challenges we’ve recently overcome and some opportunities that have emerged … Read More